FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:411-413 January 22, 2009 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mega, J. L. Related Article by Simon, T. PubMed Citation

Despite great progress in the diagnosis and treatment of unstable coronary syndromes, it is estimated that 785,000 Americans will have new acute cardiac events and 470,000 will have recurrent events this year.¹ Central to the pathogenesis of acute coronary syndromes is the adhesion and activation of platelets leading to aggregation, thrombus formation, and vessel occlusion. Unfortunately, the absolute risk of recurrent vascular events among patients taking platelet inhibitors remains relatively high.¹

The observation that platelet-dependent thrombosis occurs despite treatment with platelet inhibitors has led to a large number of studies assessing the cause of these treatment failures. Often termed "resistance," . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Boston University School of Medicine, Boston.

This article has been cited by other articles:

• Wolverton, S. E. (2009). Optimizing Clinical Use of Azathioprine With Newer Pharmacogenetic Data. Arch Dermatol 145: 707-710 [Full Text]